DeepMed Research

Tongji University Tongji Hospital of(Formerly Ganquan Hospital)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting

Conditions: Ischemic Stroke
Large-Artery Atherosclerosis (Embolus/Thrombosis)

First Posted Date: 2021-04-19

Last Posted Date: 2024-06-20

Lead Sponsor: Tongji Hospital

Target Recruit Count: 1000

Registration Number: NCT04847752

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Suspended

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: PD-1/PD-L1 inhibitor

First Posted Date: 2021-04-08

Last Posted Date: 2021-04-08

Lead Sponsor: Tongji Hospital

Target Recruit Count: 200

Registration Number: NCT04835025

Locations: 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, Hubei, P. R. China, Wuhan, Hubei, China

Effects of BRS and LRS on Postoperative Acute Kidney Injury

Phase 4

Recruiting

Conditions: Acute Kidney Injury

Interventions: Drug: Sodium Lactated Ringer's Injection
Drug: Sodium Bicarbonate Ringer's Injection

First Posted Date: 2021-04-08

Last Posted Date: 2023-04-12

Lead Sponsor: Tongji Hospital

Target Recruit Count: 3400

Registration Number: NCT04835038

Locations: 🇨🇳
Tongji hospital, Wuhan, Hubei, China

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

Phase 2

Completed

Conditions: Ovarian Clear Cell Carcinoma

Interventions: Drug: Sintilimab
Drug: Bevacizumab Biosimilar IBI305

First Posted Date: 2021-02-03

Last Posted Date: 2024-08-13

Lead Sponsor: Tongji Hospital

Target Recruit Count: 38

Registration Number: NCT04735861

Locations: 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

EUS-guided PSE in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension

Not Applicable

Conditions: Hypersplenism
Portal Hypertension
Gastroesophageal Varices

Interventions: Device: coils
Drug: cyanoacrylate glue

First Posted Date: 2021-01-05

Last Posted Date: 2021-01-08

Lead Sponsor: Tongji Hospital

Target Recruit Count: 72

Registration Number: NCT04692805

Locations: 🇨🇳
The Division of Gastroenterology, Department of Internal Medicine at Tongji Hospital, , Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients

Phase 4

Conditions: STEMI
ST Elevation Myocardial Infarction

Interventions: Drug: Oseltamivir phosphate capsules

First Posted Date: 2020-12-24

Last Posted Date: 2020-12-24

Lead Sponsor: Tongji Hospital

Target Recruit Count: 382

Registration Number: NCT04684498

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Nutrition Support for Hirschsprung Disease

Not Applicable

Completed

Conditions: Nutrition Supporting
Prospective Study
Hirschsprung Disease
Infants

Interventions: Dietary Supplement: supplement nutritional supporting

First Posted Date: 2020-10-22

Last Posted Date: 2023-04-04

Lead Sponsor: Tongji Hospital

Target Recruit Count: 110

Registration Number: NCT04598841

Locations: 🇨🇳
Tongji Hospital, Wuhan, Hubei, China

To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease With MRI

Conditions: Chronic Kidney Disease-Mineral and Bone Disorder

Interventions: Radiation: DXA

First Posted Date: 2020-09-25

Last Posted Date: 2020-09-25

Lead Sponsor: Tongji Hospital

Target Recruit Count: 200

Registration Number: NCT04564924

Locations: 🇨🇳
Tongji Hospital, Wuhan, Hubei, China

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Early Phase 1

Recruiting

Conditions: Idiopathic Inflammatory Myopathies
Neuromyelitis Optica Spectrum Disorder
Autoimmune Diseases of the Nervous System
Myasthenia Gravis
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
POEMS Syndrome
Autoimmune Diseases
Multiple Sclerosis
Autoimmune Encephalitis
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Interventions: Biological: CT103A cells
Drug: Cyclophosphamide and fludarabine

First Posted Date: 2020-09-23

Last Posted Date: 2024-10-30

Lead Sponsor: Tongji Hospital

Target Recruit Count: 36

Registration Number: NCT04561557

Locations: 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Niraparib

First Posted Date: 2020-08-11

Last Posted Date: 2024-12-17

Lead Sponsor: Tongji Hospital

Target Recruit Count: 67

Registration Number: NCT04507841

Locations: 🇨🇳
Tongji Hospital, Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy